BluWind Medical, a Park City, UT- and Herzliya, Israel-based developer of the RENOVA iStim implantable tibial neuromodulation device, raised $64M in Series B funding.
The round was led by ConvaTec.
The company intends to use the funds to grow its commercial presence in anticipation of potential FDA marketing clearance for its RENOVA iStim implantable neuromodulation device.
Led by CEO Dan Lemaitre, BluWind Medical develops the innovative RENOVA iStim implantable tibial neuromodulation device, which is under investigation for the treatment of urgency incontinence alone or in combination with urinary urgency and/or urinary frequency. RENOVA iStim is implanted near the ankle in a single short outpatient procedure of approximately 30 minutes utilizing local anesthesia.
FinSMEs
09/05/2022